Posted by Michael Wonder on 22 Feb 2020
Trulicity (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease
21 February 2020 - New indication reflects distinct patient population in the REWIND study, including primarily people with multiple cardiovascular risk factors but without established cardiovascular disease.
The U.S. FDA has approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
This decision makes Eli Lilly's Trulicity the first and only type 2 diabetes medicine approved to reduce the risk of MACE for both primary and secondary prevention populations.
